Table 2 Serum anti–vaccinia virus... | American Society of Hematology

Table 2

Serum anti–vaccinia virus antibodies and anti–vaccinia virus memory B cells in rituximab-treated (RTX) patients

Patient	Age at sample collection, y	Time after rituximab, mo	Anti-vaccinia virus IgG, serum dilution ratio	% vaccinia virus–specific memory B cells
Patient	Age at sample collection, y	Time after rituximab, mo	Anti-vaccinia virus IgG, serum dilution ratio	In blood	In spleen
RTX1	83	39	0.12	0.044	—
RTX2	61	26	0.84	0.317	—
RTX3	55	29	0.32	<0.007*	—
RTX4	45	25	0.05	0.010	—
RTX5	42	32	0.25	<0.041*	—
RTX6	79	3	ni	—†	0.140
RTX7	70	6	ni	—†	0.063
RTX8	62	15	0.47	—†	0.064
RTX9	67	2 + 36‡	0.40	0.015	—

Patient	Age at sample collection, y	Time after rituximab, mo	Anti-vaccinia virus IgG, serum dilution ratio	% vaccinia virus–specific memory B cells
Patient	Age at sample collection, y	Time after rituximab, mo	Anti-vaccinia virus IgG, serum dilution ratio	In blood	In spleen
RTX1	83	39	0.12	0.044	—
RTX2	61	26	0.84	0.317	—
RTX3	55	29	0.32	<0.007*	—
RTX4	45	25	0.05	0.010	—
RTX5	42	32	0.25	<0.041*	—
RTX6	79	3	ni	—†	0.140
RTX7	70	6	ni	—†	0.063
RTX8	62	15	0.47	—†	0.064
RTX9	67	2 + 36‡	0.40	0.015	—

ni indicates not interpretable (patient receiving intravenous Ig at the time of sample collection); and —, not applicable.

Maximum estimate for individuals for whom memory B cells were undetectable.

B-cell depletion precluded blood analyses.

Patient was splenectomized 2 months after rituximab treatment. Blood was collected 36 months after splenectomy.